Form 8-K

8-K — Glucotrack, Inc.

Accession: 0001493152-26-043844

Filed: 2026-09-23

Period: 2026-09-23

CIK: 0001506983

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001506983

2026-09-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 23, 2026

GLUCOTRACK,

INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-41141

98-0668934

(State

or Other Jurisdiction

(Commission

(IRS

Employer

Incorporation)

File

Number)

Identification

No.)

301

Rte. 17 North, Ste. 800, Rutherford, NJ

07070

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (201) 842-7715

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☒

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

GCTK

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §

230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01. Regulation FD Disclosure.

September 23, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a shareholder update. The update is

furnished as Exhibit 99.1.

The

information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the

Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates

it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Shareholder Update, dated September 23, 2026

104

Cover

Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

September 23, 2026

GLUCOTRACK,

INC.

By:

/s/

Erik Emerson

Name:

Erik

Emerson

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Lōkahi

Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development

Priorities

RUTHERFORD,

N.J., and LA JOLLA, CA: Sept. 23, 2026 — Lōkahi Therapeutics™ today issued a strategic corporate update highlighting

progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated

therapeutic assets.

Clear View of Who We Are

Message From Our CEO, Erik Emerson

Good

morning. I’m Erik Emerson, CEO of Lōkahi Therapeutics™ and Glucotrack.

many of you know, we completed our strategic business combination on July 14. Since then, we have continued to work through the post-closing

matters contemplated by the transaction, including the steps required for the conversion of the Series A convertible preferred stock,

which remains subject to applicable Nasdaq requirements and other conditions. I wanted to take this opportunity to provide an update

on where we are today, what we are building, and where we are headed next.

Over

the past year, Lōkahi Therapeutics™ has sharpened its focus around a clear objective:

build a clinical-stage biopharmaceutical company capable of discovering, advancing, and monetizing differentiated healthcare opportunities.

The

merger advanced that objective by creating a structure that allows both businesses to move forward with clarity and purpose. Today, Glucotrack

Technologies continues to operate as a wholly owned subsidiary focused on developing its continuous blood glucose monitoring technology,

while Lōkahi Therapeutics™ remains focused on therapeutic asset development, portfolio expansion, and the continued growth

of our ai² platform. In this structure, Glucotrack Technologies is funded through the resource allocation defined in the merger

agreement, while the Glucotrack parent company’s core business and financing allocations are directed to the Lōkahi Therapeutics™

business.

The

Lōkahi Therapeutics™ strategy is straightforward: identify and acquire differentiated clinical-stage assets; apply disciplined

clinical, regulatory, and operational execution to generate meaningful value-inflection data; and pursue strategic licensing, partnership,

and royalty opportunities that maximize long-term value creation. By focusing on assets that have already completed important stages

of development, we believe we can deploy capital efficiently, reduce development risk, and maintain a diversified pipeline with multiple

potential paths to future value.

Today,

our immediate priority is LT-100.

LT-100

is a biologic development program designed for the treatment of osteoarthritis knee pain. We are advancing the regulatory, clinical,

manufacturing, and operational activities necessary to support the next stage of development. A clinical protocol has been submitted

for regulatory review, and we are targeting study initiation in the near term, subject to regulatory feedback and standard development

requirements.

The

planned study will evaluate the safety and efficacy of LT-100 administered by subcutaneous injection. Building on prior clinical experience,

the study is designed to assess the safety and efficacy of once-weekly subcutaneous administration as compared to the historical regimen

of 15 weekly intradermal injections.

Today,

we are working with regulators, preparing clinical operations, advancing manufacturing readiness, and building the infrastructure required

of a clinical-stage biopharmaceutical organization to support this trial and those that may follow.

Successful

biopharmaceutical companies create value through repeatable systems that identify, evaluate, and advance new opportunities over time.

Our

Actual Intelligence platform integrates scientific, clinical, regulatory, commercial, and financial judgment into a disciplined framework

for identifying opportunities, allocating resources, and creating value. We believe technology should enhance human judgment, not replace

it.

Across

the pharmaceutical industry, billions of dollars in prior investment remain trapped in assets that have been abandoned, deprioritized,

underfunded, or overlooked. In many cases, those programs were not stopped because the science failed. They were stopped because priorities

changed, capital disappeared, or strategic focus shifted. We believe value can be created by identifying these opportunities, evaluating

them rigorously, and advancing those that meet our scientific, regulatory, commercial, and strategic criteria.

Discover.

Advance. Monetize.

Those

three principles guide how we evaluate opportunities, allocate resources, and pursue growth.

The

first component is ai² Pipeline, our asset identification and evaluation engine. Supported by a growing network of more than

14 university partners, industry collaborators, and structured evaluation processes, the platform helps us identify opportunities that

may strengthen and expand our portfolio. Today, our network applies standard pharmaceutical due diligence processes across more than

12,000 decommissioned, deprioritized, or abandoned late-stage pharmaceutical programs. Through our ai² pipeline, university undergraduates

as well as graduate participants work alongside Lokahi leadership over an 8–10-week period to assess post Phase 1 biopharma opportunities

across business development, clinical strategy, regulatory pathways, intellectual property, market assessment, and commercialization

planning. This approach identified over 45 assets that met our initial screening criteria in its first year, and we are engaged in preliminary

business development discussions with respect to certain of these opportunities.

The

second component is ai² Talent.

leverage the student relationships generated through ai² Pipeline to foster emerging talent for the industry. Through ai² Talent,

participants gain exposure to real-world pharmaceutical decision-making while contributing to meaningful strategic work. At the same

time, we are building a growing ecosystem of future leaders, analysts, operators, and innovators who may contribute to Lōkahi Therapeutics™,

our partners, and the broader biopharmaceutical industry.

The

third component is ai² Accelerator, which supports emerging technology, data, and innovation initiatives that align with our long-term

strategy and have the potential to create opportunities across the broader healthcare ecosystem. One example is Qare, an emerging

initiative being developed within the Accelerator framework. While still in its early stages, Qare reflects the type of market-driven,

technology-enabled opportunity we believe can emerge from the intersection of experienced leadership, emerging talent, and disciplined

execution.

are intentionally combining experienced operators with emerging talent.

Experience

helps us avoid mistakes.

New

perspectives help us identify opportunities.

Together,

they create a stronger organization.

The

next chapter of Lōkahi Therapeutics™ will be defined by execution.

Executing

the planned clinical program for LT-100.

Converting

ai² Pipeline candidates into in-house programs.

Launching

Qare, our first Accelerator initiative.

Growing

the ai² university network.

I close this update, I want to emphasize exactly what our business model is:

● Discover

near-term, value-creating therapeutics.

● Advance

them by enhancing process, indication, administration, or other elements that can generate

near-term value.

● Monetize

assets before completion of registration trials through a range of business development structures.

Thank

you for taking the time to learn more about Lōkahi Therapeutics™ and Glucotrack.

About

Lōkahi Therapeutics™

Lōkahi

Therapeutics™ (“Lōkahi”) is a capital-efficient biopharmaceutical platform company focused on identifying,

evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution

model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and

long-term value creation. For more information, please visit www.lokahithera.com. For more information about the ai²

Division programs, please visit www.ai2equals.com. Information on the company’s website does not constitute a part of

and is not incorporated by reference into this press release.

About

Glucotrack, Inc.

Glucotrack,

Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., focuses on the design, development,

and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring

system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For

more information, please visit www.glucotrack.com. Information on the company’s website does not constitute a part of and

is not incorporated by reference into this press release.

Forward-Looking

Statements

This

news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements

contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting

the generality of the foregoing, words such as “anticipate,” “believe,” “expect,” “may,”

“plan,” “potential,” “targeting,” and “will” are intended to identify forward-looking

statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently

available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes

no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise,

except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements,

and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized,

that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important

factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements

that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability

of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings,

strategic collaborations, or otherwise); the ability to complete the remaining post-closing approvals and preferred stock conversion

in connection with the merger transaction, including the satisfaction of required regulatory approvals; the ability of Lōkahi to

identify, evaluate, acquire, and advance therapeutic assets; the ability to advance LT-100 through clinical development; the ability

to convert pipeline opportunities identified through the ai² platform into strategic transactions; the ability to successfully develop

and commercialize new initiatives; the ability to maintain and expand academic and institutional partnerships; the ability to successfully

integrate acquired assets into Lōkahi’s pipeline; general business and economic conditions; and the additional risk factors

described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual

Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.

Contact:

Glucotrack

GlucotrackPR@icrinc.com

Lōkahi

Therapeutics™

ir@lokahithera.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Sep. 23, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 23, 2026

Entity File Number

001-41141

Entity Registrant Name

GLUCOTRACK,

INC.

Entity Central Index Key

0001506983

Entity Tax Identification Number

98-0668934

Entity Incorporation, State or Country Code

Entity Address, Address Line One

301

Rte. 17 North

Entity Address, Address Line Two

Ste. 800

Entity Address, City or Town

Rutherford

Entity Address, State or Province

Entity Address, Postal Zip Code

07070

City Area Code

(201)

Local Phone Number

842-7715

Written Communications

true

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

GCTK

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration